| TA127 |
Multiple sclerosis - natalizumab (TA127) |
|
-
-
Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis
Natalizumab is recommended as a possible treatment for people with rapidly evolving severe relapsing-remitting multiple sclerosis.
Healthcare professionals should not stop prescribing natalizumab for people with other types of multiple sclerosis who were already taking it when the guidance was issued. These people should be able to carry on taking natalizumab until they and their doctor decide that it is the right time to stop.
-
Other information
How this guidance was produced
Background information
This page was last updated: 01 February 2011
-
-
Guidance formats
-
Implementation tools and resources
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
